These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Potential memory treatment for those with Down's syndrome. Breeze S Expert Rev Clin Pharmacol; 2012 Sep; 5(5):497. PubMed ID: 23272328 [No Abstract] [Full Text] [Related]
5. Glucose effects on cognition in adults with Down's syndrome. Manning CA; Honn VJ; Stone WS; Jane JS; Gold PE Neuropsychology; 1998 Jul; 12(3):479-84. PubMed ID: 9674002 [TBL] [Abstract][Full Text] [Related]
6. Editorial: pharmacological intervention for Down syndrome cognitive deficits: emerging drug targets. Montesinos ML CNS Neurol Disord Drug Targets; 2014 Feb; 13(1):6-7. PubMed ID: 24152331 [No Abstract] [Full Text] [Related]
7. Abnormal APP, cholinergic and cognitive function in Ts65Dn Down's model mice. Seo H; Isacson O Exp Neurol; 2005 Jun; 193(2):469-80. PubMed ID: 15869949 [TBL] [Abstract][Full Text] [Related]
9. Hashimoto encephalopathy and antibodies against dimethylargininase-1: a rare cause of cognitive decline in a pediatric Down's syndrome patient. Helene V; Patrick V; Boel de P; Gini B; Bruno B; Rudy VC Clin Neurol Neurosurg; 2011 Oct; 113(8):678-9. PubMed ID: 21570763 [No Abstract] [Full Text] [Related]
10. Review of drug treatment for Down's syndrome persons. Share JB Am J Ment Defic; 1976 Jan; 80(4):388-93. PubMed ID: 2011 [TBL] [Abstract][Full Text] [Related]
11. Concerns about using Zn supplementation in Down's syndrome (DS) children. Bucci I; Napolitano G; Giuliani C; Lio S; Minnucci A; Monaco F; Di Giacomo F; Calabrese G; Palka G; Sabatino G Biol Trace Elem Res; 2001; 82(1-3):273-5. PubMed ID: 11697775 [No Abstract] [Full Text] [Related]
12. Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Fernandez F; Morishita W; Zuniga E; Nguyen J; Blank M; Malenka RC; Garner CC Nat Neurosci; 2007 Apr; 10(4):411-3. PubMed ID: 17322876 [TBL] [Abstract][Full Text] [Related]
14. Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease. Rumble B; Retallack R; Hilbich C; Simms G; Multhaup G; Martins R; Hockey A; Montgomery P; Beyreuther K; Masters CL N Engl J Med; 1989 Jun; 320(22):1446-52. PubMed ID: 2566117 [TBL] [Abstract][Full Text] [Related]
15. [Down's syndrome. Medical complications]. Hestnes A Tidsskr Nor Laegeforen; 1987 Jan; 107(1):14-6. PubMed ID: 2950613 [No Abstract] [Full Text] [Related]
16. Clinical trials in children with Down syndrome: issues from a cognitive research perspective. Heller JH; Spiridigliozzi GA; Crissman BG; Sullivan-Saarela JA; Li JS; Kishnani PS Am J Med Genet C Semin Med Genet; 2006 Aug; 142C(3):187-95. PubMed ID: 16838317 [TBL] [Abstract][Full Text] [Related]
17. [Screen and identify of differential proteins expressed in the placenta of Down's syndrome]. Yan LY; Sun CJ; Wang X; Chen Y; Zhang WY Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):161-6. PubMed ID: 21575446 [TBL] [Abstract][Full Text] [Related]
18. Socio-cognitive understanding: a strength or weakness in Down's syndrome? Wishart JG J Intellect Disabil Res; 2007 Dec; 51(Pt 12):996-1005. PubMed ID: 17991007 [TBL] [Abstract][Full Text] [Related]
19. Oxidative stress: a bridge between Down's syndrome and Alzheimer's disease. Zana M; Janka Z; Kálmán J Neurobiol Aging; 2007 May; 28(5):648-76. PubMed ID: 16624449 [TBL] [Abstract][Full Text] [Related]